Once-nightly pill treats causes of airway collapse to control obstructive sleep apnea in large clinical trial (opens in new tab)

A once-nightly oral pill helped control obstructive sleep apnea in a large, Phase III clinical trial presented at the 2026 ATS International Conference. The drug, called AD109, is the first therapy to treat OSA by addressing its underlying mechanisms and targeting the neuromuscular causes of airway collapse.